CELG:NGS-Celgene Corporation

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 84.28

Change

0.00 (0.00)%

Market Cap

USD 59.28B

Volume

2.54M

Average Target Price

USD 109.18 (29.54%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-10-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

+0.43 (+0.21%)

USD 131.25B
GILD Gilead Sciences Inc.

-0.69 (-0.90%)

USD 98.03B
BIIB Biogen Inc.

-0.38 (-0.11%)

USD 68.13B
SHPG Shire plc

+1.85 (+1.05%)

USD 54.08B
VRTX Vertex Pharmaceuticals Incorpo..

+0.03 (+0.02%)

USD 47.40B
REGN Regeneron Pharmaceuticals Inc.

+0.54 (+0.14%)

USD 43.12B
ALXN Alexion Pharmaceuticals Inc.

+1.24 (+0.97%)

USD 28.74B
BMRN BioMarin Pharmaceutical Inc.

+0.06 (+0.06%)

USD 18.84B
INCY Incyte Corporation

+0.13 (+0.20%)

USD 13.83B
GRFS Grifols S.A.

-0.04 (-0.20%)

USD 13.49B

ETFs Containing CELG

IBB iShares Nasdaq Biotechnol.. 7.27 % 0.47 %

-0.06 (-0.05%)

USD 9.22B
BIB ProShares Ultra Nasdaq Bi.. 5.62 % 0.95 %

-0.21 (-0.34%)

USD 0.36B
BBH VanEck Vectors Biotech ET.. 4.97 % 0.35 %

+0.17 (+0.14%)

USD 0.45B
UBIO Proshares UltraPro Nasdaq.. 4.53 % 0.95 %

-0.16 (-0.44%)

USD 0.03B
ARKG ARK Genomic Revolution Mu.. 3.99 % 0.75 %

-0.01 (-0.03%)

USD 0.02B
SYG SPDR MFS Systematic Growt.. 3.48 % 0.60 %

-0.10 (-0.12%)

USD 0.05B
DWSH AdvisorShares Dorsey Wrig.. 2.07 % 0.00 %

-0.41 (-1.54%)

USD 0.01B
LNGR Global X Longevity Themat.. 0.00 % 0.52 %

-0.21 (-1.00%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.24% 46% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.24% 45% F 25% F
Trailing 12 Months  
Capital Gain -39.31% 34% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.31% 33% F 14% F
Trailing 5 Years  
Capital Gain 5.35% 59% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.35% 58% F 37% F
Average Annual (5 Year Horizon)  
Capital Gain 7.13% 52% F 50% F
Dividend Return 7.13% 52% F 46% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.56% 76% C 46% F
Risk Adjusted Return 24.95% 59% F 41% F
Market Capitalization 93.78B 99% A+ 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.09 4% F 23% F
Price/Book Ratio 8.92 20% F 12% F
Price / Cash Flow Ratio 4.20 6% F 25% F
Price/Free Cash Flow Ratio 17.41 5% F 28% F
Management Effectiveness  
Return on Equity 37.04% 89% B+ 92% A-
Return on Invested Capital 10.52% 87% B+ 71% C-
Return on Assets 8.88% 94% A 87% B+
Debt to Equity Ratio 233.75% 7% F 9% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

CELG:NGS-Celgene Corporation

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 84.28

Change

0.00 (0.00)%

Market Cap

USD 59.28B

Volume

2.54M

Average Target Price

USD 109.18 (29.54%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-10-17